Table 3.
Activities of compounds on human tumor cell viability
| Compound ID | A549
|
HTC116
|
MiaPaCa-2
|
SKOV-3
|
SW480
|
PC-3
|
SK-BR-3
|
K562
|
MDA-MB-231
|
A498
|
HT-29
|
Jurkat
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IC50 (M) | IC50 (M) | IC50 (M) | IC50 (M) | IC50 (M) | IC50 (M) | IC50 (M) | IC50 (M) | IC50 (M) | IC50 (M) | IC50 (M) | IC50 (M) | |
| Ebselen | >1.00E–04 | 2.59E–05 | 4.03E–05 | 7.81E–05 | 9.24E–05 | >1.00E–04 | 9.27E–05 | 1.30E–05 | >1.00E–04 | >1.00E–04 | 6.35E–05 | 1.38E–05 |
| Ebselen oxide | >1.00E–04 | >1.00E–04 | 3.41E–05 | >1.00E–04 | 1.10E–04 | >1.00E–04 | >1.00E–04 | 1.51E–05 | 8.36E–05 | 4.71E–05 | 9.35E–05 | 7.95E–05 |
| Thr101 | 1.82E–05 | 9.03E–06 | 1.07E–05 | 1.98E–05 | 6.29E–06 | 2.52E–05 | 1.58E–05 | 4.50E–06 | 2.17E–05 | 3.00E–05 | 2.06E–05 | 1.24E–05 |
| RBC-2004 | 3.89E–05 | 9.64E–06 | 3.00E–05 | 2.44E–05 | 7.53E–06 | >1.00E–04 | 3.37E–05 | 5.94E–06 | 2.67E–05 | 4.01E–05 | 2.61E–05 | 1.36E–05 |
| RBC-2008 | >1.00E–04 | 2.96E–05 | 1.81E–05 | >1.00E–04 | >1.00E–04 | >1.00E–04 | 2.81E–05 | 1.71E–05 | 3.16E–05 | >1.00E–04 | 7.93E–05 | 6.40E–06 |
| RBC-2010 | >1.00E–04 | 2.04E–05 | 1.82E–05 | 2.20E–05 | 8.35E–06 | 2.08E–05 | 4.10E–05 | 4.90E–06 | 1.86E–05 | 4.51E–05 | 3.12E–05 | 7.57E–06 |
| ACY-1215 | >1.00E–04 | 6.56E–06 | 7.38E–06 | 1.42E–05 | 9.55E–06 | >1.00E–04 | 1.09E–05 | 1.12E–05 | 1.58E–05 | 6.21E–05 | 1.86E–05 | 4.40E–06 |
| Tubastatin A | >1.00E–04 | 2.31E–05 | 1.96E–05 | 3.86E–05 | 3.31E–04 | >1.00E–04 | 6.28E–06 | 3.42E–05 | 1.68E–05 | >1.00E–04 | >1.00E–04 | .1.00E–04 |
| SAHA | 2.00E–05 | 6.55E–07 | 3.23E–06 | 1.28E–05 | 3.54E–06 | 2.15E–05 | 1.23E–06 | 2.36E–06 | 3.85E–06 | 1.38E–05 | 3.74E–06 | 7.92E–07 |
Abbreviations: IC50, half maximal inhibitory concentration; SAHA, suberoylanilide hydroxamic acid.